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Abstract: O6-carboxymethylguanine (O6-CMG) is a highly mutagenic 
alkylation product of DNA, triggering transition mutations relevant to 
gastrointestinal cancer. However, precise localization of a single O6-
CMG with conventional sequencing platforms is challenging. Here 
nanopore sequencing, which directly senses single DNA bases 
according to their physiochemical properties, was employed to detect 
O6-CMG. A unique O6-CMG signal was observed during nanopore 
sequencing and a single-event call accuracy of >95% was achieved. 
Moreover, O6-CMG was found to be a replication obstacle for Phi29 
DNA polymerase (Phi29 DNAP), suggesting this lesion could cause 
DNA sequencing biases in next generation sequencing approaches. 
Depurinations,[1] base modifications[2] or DNA strand breaks[3] 
occur regularly in the genome as a result of exposure to 
endogenous or exogenous agents.[4] These can interfere with the 
high-fidelity transmission of genetic information[5] or lead directly 
to cell death[6] if they are not repaired. Alkylated DNA adducts are 
often carcinogenic,[7] and are formed by the attack of electrophilic 
alkylating agents on the nitrogen or oxygen atoms of DNA 
bases.[8] While attack by these agents is thought to have low 
sequence specificity, recent efforts have shown that it is the 
selectivity of DNA repair rather than the selectivity of the initial 
damage that determines mutational hotspots. For example, with 
cisplatin[2a, 7, 9] and dihydropyrimidine dimers,[10] densely packed 
heterochromatic regions and transcription factor binding sites are 
most prone to mutation.[11] Studies of this sort highlight the need 
for single nucleotide resolution in sequencing DNA lesions. 
O6-alkyl adducts at guanine are potent mutagens,[12] which 
occur naturally[13] or during chemotherapy.[14] O6-
Carboxymethylguanine (O6-CMG, Fig. 1a) is an important O6G 
lesion because it shows a high tendency to cause miscoding in 
DNA replication.[15] Indeed its appearance in vivo is proportional 
to the consumption of red meat and may lead to colorectal 
cancer.[16] Precise detection of O6-CMG within the genome is 
important to unveil the mechanisms of its formation, to determine 
whether certain sites are resistant to repair,[11a] or to explore its 
potential as a tumor biomarker.[17] O6-CMG has only been 
detected by immunoaffinity-HPLC fluorescence assay or LC-
MS/MS,[9b] which require a lot of sample,[18] a poorly available 
antibody,[19] or lose sequence information because of strand 
digestion.[20] Hence, no current method can directly localize 
individual O6-CMG bases within a stretch of DNA. Nanopore 
sequencing (NPS)[21] would seem to be the ideal platform for 
characterizing DNA lesions because it achieves base-calling by 
directly measuring a property of the molecule; additionally NPS is 
amplification-free, has single-nucleotide resolution, and can read 
non-canonical bases.[22] 
Figure 1. Structure and synthesis of DNA with O6-CMG lesions. a) The O6-
CMG lesion occurs in DNA and is a potent mutagen, leading to G→A transition 
mutations. b) Six DNA strands bearing zero to two O6-CMG lesions at different 
positions were synthesized. c) Solid-phase oligonucleotide synthesis with a 
modified phosphoramidite and one (82-mer DNAs) or two (92-mer DNAs) splint 
mediated ligation steps deliver all of the oligonucleotides for NP testing. 
In the present study, NPS was used to identify O6-CMG lesions 
in various locations within synthetic DNA strands (Fig. 1c). The 
lesions were unambiguously spotted according to their 
characteristic signals in the Mycobacterium smegmatis porin A 
(MspA) nanopore (NP) assisted by Phi29 DNAP (see the 
electronic supporting information (ESI) for details)[23] with a single 
event call accuracy of >95.2%. The data also reveals that O6-
CMG is a potent replication obstacle for Phi29 DNAP both at the 
single molecule level and in ensemble. Our results demonstrate 
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the first sequencing strategy for O6-CMG while also highlighting 
the potential of single molecule studies for understanding 
enzymatic activities. 
Sequence information from MspA NPS is inferred by reading 
different combinations of sequence quadromers simultaneously 
occupying the pore restriction.[23]  According to the published 
quadromer map,[23] AGAA and CTTT report the highest and the 
lowest current level respectively as they pass through the MspA 
NP. According to the enzymatic ratcheting mechanism of NPS,[22a] 
sequential NP reading of a CTTTAGAACTTT sequence segment 
yields an asymmetric triangle-shaped current signature with nine 
successive current steps cycling between the lowest (CTTT) and 
highest (AGAA) signals. In this work, DNA templates to be 
sequenced were designed to contain four of these highly 
distinguishable AGAACTTT cycles (Fig. 1b, Table S1). 
To evaluate the NP sensing ability of O6-CMG, a set of 
oligonucleotides bearing the lesion at different sites were 
prepared. The syntheses began with a phosphoramidite prepared 
by a copper-catalyzed O6G alkylation with commercially available 
ethyldiazoacetate, as described previously (Fig. S1, S2).[24] With 
this phosphoramidite, O6-CMG bearing 27-mer DNAs with a 5’-
alkyne tag were prepared by solid-phase synthesis (Fig. S3) and 
then coupled to a 5’-phosphorylated canonical 55-mer DNA using 
a T4 splint ligation (Fig. 1c). The resulting 82-mer DNAs could be 
further extended to the longer 92-mers containing a 
deca(deoxythymidine) tag, by performing a splint-mediated Cu-
catalyzed azide alkyne cycloaddition. Using this approach, three 
82-mers (DNA-2, DNA-3, DNA-4) and one 92-mer DNA template 
(DNA-6), which contain O6-CMG modifications, were produced, in 
addition to the necessary unmodified reference strands (DNA-1 & 
DNA-5). The 82-mers were used to study the performance of O6-
CMG spotting by NPS while the 92-mers were used for the single 
molecule studies of Phi29 DNAP. 
 
 
Figure 2. Direct spotting of O6-CMG by NPS. a) Schematic of O6-CMG 
reading during NPS. The DNA library is composed of the template strand (which 
contains the O6-CMG, red dot), the primer strand and the blocker (purple). In an 
applied electric potential, the DNA library was electrophoretically driven into the 
MspA NP (blue). (i) The scenario of voltage-driven unzipping (black arrows) and 
replication-driven (Phi29 DNAP, green) ratcheting (red arrow) represents the 
initiation of NPS. (ii) O6-CMG on the template strand is spotted when it enters 
the pore constriction. (iii) The analyte escapes from the NP as the end of the 
template strand is reached. b) A representative electrophysiology trace from 
NPS of DNA-2 (Table S1). The red segment of the trace (flickering) is diagnostic 
for O6-CMG in the restriction (Fig. S9). c) Statistical signal pattern of DNA-2. 
The means and standard deviations are from independent sequencing trials 
(N=20). The higher signal around step 21 is the O6-CMG. 
NPS was carried out using the enzymatic ratcheting strategy[22a] 
with a mutant MspA NP[22c, 25] (see ESI) inserted in a self-
assembled 1,2-diphytanoyl-sn-glycero-3-phosphocholine 
(DPhPC) lipid bilayer, which separates the cis and the trans side 
of a custom-made electrophysiology chamber.[21a] Wildtype Phi29 
DNAP was used in the cis side of the chamber to promote the 
DNA copying for NPS (fully described in the ESI, Fig. S4). The 
sequencing library is composed of three parts: the DNA template 
to be sequenced, the blocker for preventing the DNA template 
from being extended by Phi29 DNAP in solution and the primer 
for initiating DNA replication (Table S1).[22b] Synthetic ssDNAs 
DNA-n (n=1-6, Fig. 1b, Table S1) were thermally annealed with 
the primer and the blocker strands by published protocols (see 
ESI).[22b] The 5’ end of the DNA template was electrophoretically 
driven into the pore first, thereby releasing the blocker strand (Fig. 
2ai).[26] This was followed by the Phi29 DNAP-driven primer 
extension (Fig. 2aii-iii). NPS signals appear as step transitions 
during stages ii and iii following a 3’-5’ order of signal appearance 
 
 
 
 
until the template-primer complex escapes the pore (Fig. 2aiii). 
The template strand DNA-1 (Table S1), which is composed only 
of canonical DNA bases, was taken as a reference strand for NPS. 
Four consecutive triangle-shaped current segments (derived from 
the four sequence repeats of AGAACTTT) were consistently 
monitored from the raw electrophysiology traces (Fig. S5). A 
zoomed-in view of a single period of the signal shows detailed 
steps within the sequencing trace, in which AGAA and CTTT 
report the highest and the lowest level of NP readout, respectively. 
The asymmetric pattern of the NPS signal inherent to this 
particular sequence design is helpful to identify abnormal 
backward motion of the enzyme, which occasionally occurs 
during NPS.[22a] 
NPS of DNA-1 generates signals with high consistency across 
many independent sequencing events (see Fig. S6 for statistics 
and normalization procedure). Other DNA-n strands (n=2-6, Table 
S1), which contain identical sequences but with specific alkylated 
guanines, are expected to give similar current signals except at 
locations with O6-CMG. For example, DNA-2 contains a single O6-
CMG replacement located in the 3rd cycle of the sequence repeats. 
As expected, four cycles of triangular shaped signals were 
consistently recorded when DNA-2 was NP sequenced. In 
contrast to DNA-1, however, an abnormally high and flickering 
signal was observed around the peak of the 3rd cycle, consistent 
with the location of the O6-CMG nucleotide (Table S1, Fig. 2b). 
This distinctive signal level, which corresponds to NP reading of 
AG*AA (G*=O6-CMG) instead of AGAA in the reference (DNA-1, 
Fig. S5-S6) was observed consistently as demonstrated in 
statistics from 20 independent NPS reads of DNA-2 (Fig. 2c). After 
normalization of the traces, the mean amplitude difference 
between the statistical values acquired from DNA-2 and DNA-1 
demonstrates a ~10 pA difference (Fig. S8) around the location of 
an O6-CMG in DNA-2. Among all the quadromer combinations of 
canonical bases, the NP reading of AGAA reports the largest NPS 
current level.[23] NP reading of AG*AA (G*=O6-CMG), however, 
reports a further elevation of 10 pA above the AGAA readout, 
which clearly differentiates the AG*AA readout from that of all 
other base combinations. In addition, characteristic trace 
flickering was recorded whenever AG*AA reached the NP 
restriction (red segment, Fig. 2b). The trace flickering, which 
appears as forward and backward step transitions between 
AG*AA and G*AAC, may result from either dangling motions of 
the carboxylmethyl group of O6-CMG or the protonation 
equilibrium of the acid (Fig. S9). Both the high current step and 
the flickering signal are unique criteria that can be used to identify 
O6-CMG. 
To estimate the call accuracy of O6-CMG in DNA-2, the 
highest current level, which corresponds to NP reading of AG*AA, 
was taken as the judgement criterion. There were 42 raw 
sequencing events in the statistics, and in only two cases did the 
AG*AA signal fail to reach the expected level, giving a single-
event spotting accuracy of 95.2% (Fig. S10). The 4.8% of failed 
reads may result from either too short an acquisition time for the 
O6-CMG occupying the pore restriction or hydrolysis of the 
carboxymethyl group from the base. Nevertheless, we conclude 
conservatively that the single-event spotting accuracy is more 
than 95.2% under the conditions tested.  
DNA-3 and DNA-4 (Fig. 1b, Table S1) were sequenced next; 
these are identical to DNA-1 except for one (DNA-3) or two (DNA-
4) O6-CMG base replacements at different positions. To highlight 
the robustness of O6-CMG reading during NPS, the statistical 
mean differences between DNA-2, 3 and 4 compared to DNA-1 
are summarized in Fig. 3. To avoid pore-to-pore variations, current 
traces were normalized before the derivation of the statistical 
results. The results (Fig. 3, Fig. S11-S12) show that different 
quantities or locations of O6-CMG can be unambiguously spotted 
by a consistent 10 pA elevated current relative to the reference 
strand. 
 
Figure 3. Mean current differences relative to DNA-1 between DNAs 
possessing different O6-CMG sites. DNA-2, 3, 4 (Table S1), contain different 
O6-CMG sites within the sequence. O6-CMGs in each template are marked as 
G* in red within the sequence below each chart (a-c). Red lines in each charts 
show the mean current differences between alkylated DNAs and the reference 
(DNA-1, Table S1). 20 readouts from each template were used to form the 
statistics. Black bars on red lines show the standard deviations of alkylated 
DNAs while the gray columns along the x-axis show the standard deviations 
from DNA-1. a) DNA-2 b) DNA-3 c) DNA-4. From a-c, a mean current difference 
of ~10 pA was observed between O6-CMG and guanine. 
 
 
 
 
Next the interaction of the O6-CMG lesion with Phi29 DNAP was 
analyzed using the NP as a molecular tweezer. A NP tweezer is a 
device where a known DNA sequence serves as a molecular ruler 
as it is ratcheted out of the pore during sequencing.[27] In the 
present case, the NPS setup could be used to probe Phi29 DNAP 
activity as it meets O6-CMG on the single molecule level with a 
spatial resolution as low as ~40 pm. The height of the MspA NP 
requires ~15 nucleotides to span from the NP restriction to bulk 
solvent, where Phi29 DNAP is located.[28] Although the 82-mer 
DNAs (DNA2-4 in Fig. 1b and Table S1) would be just long enough 
to reach out of the pore, the reduced electrophoretic force (fewer 
charges remaining in the pore) would allow the DNA to escape 
the pore too quickly by Brownian motion. Hence 92-mer DNAs 
(DNA-5 and DNA-6, see Fig. 1c for synthesis and Table S1 for 
precise structures) bearing a 10-thymidine tail installed through a 
triazole linkage were used in the molecular tweezers experiments. 
As expected, DNA-5, which contains no O6-CMG, delivers a 
nearly identical NPS signal as DNA-1 (Fig. S13). However, due to 
the added length of DNA at the 5’ end of DNA-5, more sequencing 
events could be recorded (Fig. S13a). All NPS signals acquired 
from DNA-5 end with spontaneous pore restoration, which means 
that the added triazole linker and the extra 10-thymidine tag itself 
cannot hold DNA-5 efficiently in the pore restriction. DNA-6 (Table 
S1) is identical to DNA-5 except that it bears an O6-CMG 
nucleotide replacement at position thirty-two. Hence comparing 
DNA-5 and DNA-6 should provide information on the single 
molecule interaction of the O6-CMG with the Phi29 DNAP (Fig. 
4a). During NPS of DNA-6 (Fig. 4b) four consecutive peaks 
appeared with an elevated signal in the 3rd peak of the trace (first 
0.6 seconds), fully consistent with the data of DNA-2. However, 
this was followed by a halt of the enzymatic activity and a 
flickering signal a further ~16 steps (i.e. nucleotides) beyond the 
appearance of the O6-CMG signal (Fig. 4bii’ and Fig. 4c for zoom-
in). This single molecule enzymatic halt phenomenon, which is 
observed in 98.3% of the events acquired from DNA-6, is never 
observed with the control sample DNA-5 (Fig. S14). Hence the 
single molecule NP tweezers assay implies that the O6-CMG acts 
as a replication obstacle for Phi29 DNAP in at least 98% of their 
encounters. To compare these results with ensemble activity of 
Phi29 DNAP we performed a polymerase extension assay. To 
avoid interference from the triazole linker, DNA-1 and DNA-2 were 
used in the polymerase extension assay. DNA-1, which contains 
no alkylated DNA bases, is extended to the full-length product, as 
marked by position 1 (Fig. 4d). DNA-2, which contains a single 
O6-CMG nucleotide within its sequence, shows a strong stopping 
band (marked as position 2 on the gel, Fig. 4d). Combined with 
the results from the single molecule assay, it is clear that O6-CMG 
acts as a replication obstacle for Phi29 DNAP. The fact that most 
of DNA-2 is fully copied (despite the 98% blocking frequency 
suggested in the single molecule assay) is likely an indication that 
Phi29 DNAP repeatedly attempts to copy beyond O6-CMG over 
the 20-minute timeline of the experiment. 
  
Figure 4. Single-molecule and ensemble experiments establishing O6-
CMG as a replication obstacle of Phi29 DNAP. a) Schematic of the molecular 
tweezer assay. The 92-mer DNA-6 (Table S1) provides enough length for the 
CMG lesion to encounter Phi29 DNAP. (ii’) O6-CMG (red dot) can be spotted as 
it translocates through the pore constriction. The red arrow indicates the 
direction of motion of the DNA template when ratcheted by the Phi29 DNAP 
during DNA replication. (iii’) When O6-CMG reaches the binding pocket of the 
Phi29 DNAP, further DNA replication stops. b) A representative current trace 
acquired from DNA-6 during the single molecule assay. Characteristic signals 
of O6-CMG (ii’, the red segment) were first observed. After subsequent chain 
elongation of ~14 bases, repetitive fluctuating (iii’) without further elongation is 
observed, indicating that O6-CMG is an obstacle for Phi29 DNAP. c) A zoom in 
of the first 1.5 seconds of the tweezer assay shows a 16’-17’ nucleotide phase-
shift between AG*AA reading and the subsequent enzymatic halt (Fig. S14), 
after which the flickering signal is observed. d) A gel assay establishes O6-CMG 
as a replication obstacle for Phi29 DNAP in ensemble (conditions in the ESI). 
In summary, we have demonstrated that the mutagenic DNA 
lesion O6-CMG can be read by direct NPS. Abnormally high 
current readouts with flickering characteristics were observed 
when O6-CMG occupied the pore restriction during NPS. Assisted 
by these unique signal features, a single-event call accuracy of 
95.2% was achieved for O6-CMG reading. As the first 
demonstration of direct O6-CMG detection in a single molecule, 
this work opens the door for more precise characterization of O6-
CMG in cellular DNA, which at present would be challenging to 
sequence with single-nucleotide resolution with any NGS platform. 
The conclusions in this paper suggest that the commercially 
available MinIonTM sequencer could directly identify O6-CMG in 
DNA samples.  
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